Credit score: Unsplash/CC0 Public Area
New analysis being introduced at this 12 months’s European Congress on Weight problems (ECO 2025, Malaga, Spain, 11–14 Could) exhibits that girls are far more conscious of and educated concerning the weight problems medication GLP-1/GIP receptor agonists (that embrace semaglutide and tirzepatide).
The examine is by Nadja Auerbach, Voy, London, UK, and Dr. Austen El-Osta, Director of the Self-Care Educational Analysis Unit (SCARU) on the College of Public Well being, Imperial Faculty London, UK, and colleagues.
A number of randomized managed trials have demonstrated that therapy with glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs) results in substantial weight reduction. GLP-1/GIP RA use is rising worldwide and a nationwide roll-out of tirzepatide (model title Mounjaro) is forthcoming within the UK Nationwide Well being Service.
Understanding public views on GLP-1/GIP RAs might inform approaches supporting equitable therapy rollout and uptake, and can assist establish goal areas for training to advertise knowledgeable decision-making.
The authors performed a examine of UK adults utilizing the Imperial Faculty Qualtrics digital survey platform between 10 Oct to 12 Nov 2024. Individuals have been recruited to the examine via Voy and its associates’ mailing lists, and utilizing partnering organizations and group teams and social media channels resembling X and LinkedIn.
The survey included 45 questions protecting data and attitudes to GLP-1/GIP RA use, weight-loss behaviors and stage of settlement with statements concerning GLP-1/GIP RAs. Information have been analyzed utilizing statistical modeling.
A complete of 1,297 adults accomplished the survey: median age 44 years, and median BMI of 28.4 kg/m2. Over a 3rd (35%) recognized as male, 62% as feminine, 0.3% chosen different, and 0.3% opted to not disclose. Among the many contributors, 196 (17%) have been from non-white ethnic teams. 72.6% reported weight-loss makes an attempt within the final 12 months; 432 (33.3%) reported greater than 10 years of tried weight reduction.
A complete of 1,036 (80%) reported consciousness of GLP-1 / GIP RAs, with ladies considerably extra seemingly than males to report each increased consciousness (87% vs. 68%) and glorious understanding (20% vs. 8%) of GLP-1/GIP RAs. A complete of 359 contributors (35%) reported present use of those weight problems medication, 85% reported prior use, and 111 (11%) reported curiosity in use.
An understanding of potential negative effects (81%), effectiveness of the remedy (79%), and skill to keep up weight-loss outcomes (67%) have been necessary/essential elements in deciding to make use of GLP-1/GIP RAs. Considerations round security (67%), potential negative effects (65%) and threat of weight acquire after discontinuation (65%) have been recognized as key obstacles to commencing GLP-1/GIP RAs.
These at present or beforehand utilizing GLP-1RAs have been extra seemingly to provide opinions in favor of their use—they have been round seven occasions extra seemingly than non-users to strongly disagree with the statements of skepticism that “risks outweigh the benefits” and “there is not enough evidence to suggest GLP-1RAs are safe.”
The authors conclude, “There may be excessive consciousness of those newer era weight problems medicines within the normal inhabitants. Considerations concerning security profiles, negative effects and threat of weight re-gain after discontinuation have been among the many main perceived obstacles to initiating GLP-1/GIP receptor agonists in folks not at present utilizing them.
“These at present utilizing these medicines understand them as protected and efficient, and advocate for wider accessibility. Causes for uncertainty and skepticism in folks not utilizing GLP-1RAs spotlight avenues for improved public info to help equitable roll-out and uptake of novel medicines for weight problems.
“A new wave of digital health providers are emerging, including Voy, who co-authored this research, with a mission to improve safe and timely access to these life-changing medications.”
Offered by
European Affiliation for the Examine of Weight problems
Quotation:
Examine finds ladies more likely to concentrate on and have good understanding of weight problems medication (2025, April 18)
retrieved 19 April 2025
from https://medicalxpress.com/information/2025-04-women-aware-good-obesity-drugs.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
